Today we'll be speaking with Grey Wolf Therapeutics to hear about their astounding work with ERAP inhibition to target antigen presentation in tumour cells. This novel direction is broadly applicable across many tumour types, and we'll learn about exciting exploration of the peptide library to develop specific therapies along with potential next steps for pairing with T-cell treatment.